Cell Cycle Inhibitors in Cancer Therapy: Current Strategies (Cancer Drug Discovery and Development)

Leading clinicians and investigators review in a comprehensible and user-friendly style all the latest information about the molecular biology of cell cycle control and demonstrate its clinical relevance to understanding neoplastic diseases. Topics range from Cdk inhibitors and cell cycle regulators to the prognostic value of p27 and tumor suppressor genes as diagnostic tools. Actual case studies show how the new molecular understanding has produced such drugs as Flavopiridol and Sulindac. The book brings all the recent critical research findings to bear on clinical practice, and clearly shows their powerful impact on the diagnostics, prognostics, and therapeutics of cancer, AIDS, and cardiovascular disease.

The molecular approach to disease continues to yield a tremendous amount of new information about those aspects of cellular replication that we use to understand, prevent, diagnose, and cure cancer. In Cell Cycle Inhibitors in Cancer Therapy: Current Strategies, recognized clinicians and investigators review in a comprehensible and user-friendly style all the latest information about the molecular biology of cell-cycle control and demonstrate its clinical relevance to understanding neoplastic diseases. Topics range from Cdk inhibitors and cell cycle regulators to the prognostic value of p27 and tumor-suppressor genes as diagnostic tools. Actual case studies show how the new molecular understanding has produced such drugs as Flavopiridol and Sulindac.
Up-to-date and richly instructive, Cell Cycle Inhibitors in Cancer Therapy: Current Strategies brings all the recent critical research findings to bear on clinical practice, and clearly shows their powerful impact on the diagnostics, prognostics, and therapeutics of cancer, AIDS, and cardiovascular disease.